Xilio Therapeutics, Inc.: financial statements

XLONASDAQHealthcare · Pharmaceutical Preparations

Price

$7.70

November 19, 2026Market cap $54M

What Ploutos Investor adds for Xilio Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 2 fiscal years, from 2024
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2024–2025 fiscal years

Click a line to see it on the chart.

Revenue

Line20242025Average a year
Revenue $6.3M$44M
Operating income -$61M-$42M
Net income -$58M-$35M
Earnings per share -$15.24-$4.19
Earnings per share, basic -$15.24-$4.19
Margins
Operating margin -954.9%-95.9%
Net margin -918.0%-80.1%

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$7.0M Leases0.0% Effective tax rate

Leases

Dec 31, 2025

Operating leases

$7.0M

Finance leases

–

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

0.0%

-21.0 pts

The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.

The lines the company states do not reach its effective rate, so we do not show them. Both rates are the filing's. The filing

The full analysis

What do Xilio Therapeutics's filings show?

These are Xilio Therapeutics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about XLO's financials

Didn't find what you were looking for?

Ask us
How much revenue did XLO have in 2025?

Xilio Therapeutics had revenue of $44M and net income of -$35M in fiscal 2025, a net margin of -80.1%.

How much debt does XLO have?

On December 31, 2025 Xilio Therapeutics had total assets of $155M, debt of – and shareholders' equity of $35M.

How much free cash flow does XLO have?

In fiscal 2025 Xilio Therapeutics had cash from operations of -$5.0M and spent $518.0K on capital expenditure, leaving -$5.5M of free cash flow.

Where are the figures from?

From Xilio Therapeutics, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.